Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders.


Journal

JBRA assisted reproduction
ISSN: 1518-0557
Titre abrégé: JBRA Assist Reprod
Pays: Brazil
ID NLM: 101684552

Informations de publication

Date de publication:
30 04 2019
Historique:
pubmed: 8 1 2019
medline: 26 6 2020
entrez: 8 1 2019
Statut: epublish

Résumé

Transdermal testosterone has been used in different doses and in different stimulation protocols in poor responders. The aim of the present study is to compare the luteal estradiol/GnRH antagonists protocol versus long GnRH agonists in poor responder patients according to the Bologna criteria, in which transdermal testosterone has been used prior to the stimulation with gonadotropins. In this retrospective analysis, a total of 141 poor responder patients according to the Bologna criteria were recruited. All patients were treated with transdermal testosterone preceding ovarian stimulation with gonadotropins during 5 days. In 53 patients we used the conventional antagonist protocol (Group 1). In 88 patients (GrH pituitary suppression was achieved by leuprolide acetate according to the conventional long protocol (Group 2). We analyzed the ovarian stimulation parameters and IVF outcomes. Comparing groups 1 and 2, there were no significant differences between cancellation rates and number of oocytes retrieved. However the total gonadotropin dose used and the mean length of stimulation were significantly lower in group 1 when compared to group 2. There were no significant differences in pregnancy outcomes; however, there was a slight increase in the implantation rate in group 1 vis-a-vis group 2, although statistical significance was not achieved. TT in poor responder patients can be effective both with the conventional agonist's long protocol and with the conventional antagonist's protocol. However, short regimes with previous estradiol antagonists in the luteal phase facilitate ovarian stimulation by shortening the days of treatment and the consumption of gonadotropins.

Identifiants

pubmed: 30614665
doi: 10.5935/1518-0557.20180090
pmc: PMC6501741
doi:

Substances chimiques

Hormones 0
Gonadotropin-Releasing Hormone 33515-09-2
Testosterone 3XMK78S47O
Estradiol 4TI98Z838E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-136

Références

Semin Reprod Med. 2015 Nov;33(6):436-48
pubmed: 26562286
J Control Release. 2000 Mar 1;65(1-2):303-15
pubmed: 10699290
J Clin Endocrinol Metab. 2003 Dec;88(12):5957-62
pubmed: 14671196
J Clin Endocrinol Metab. 1999 Aug;84(8):2951-6
pubmed: 10443703
Biomed Res Int. 2014;2014:352098
pubmed: 25136579
J Reprod Fertil. 1993 Nov;99(2):403-13
pubmed: 8107022
J Clin Invest. 1998 Jun 15;101(12):2622-9
pubmed: 9637695
Hum Reprod. 2006 May;21(5):1204-11
pubmed: 16476678
J Clin Endocrinol Metab. 1986 Jan;62(1):16-21
pubmed: 3940265
Hum Reprod. 2013 Nov;28(11):2981-9
pubmed: 23887073
Hum Reprod. 2011 Jul;26(7):1616-24
pubmed: 21505041
Hum Reprod. 2016 May;31(5):977-85
pubmed: 26956551
Hum Reprod. 2006 Jul;21(7):1884-93
pubmed: 16517559
Reprod Sci. 2018 Jul;25(7):980-982
pubmed: 27489169
Reprod Biomed Online. 2012 Nov;25(5):450-9
pubmed: 22999555
Hum Reprod. 2012 Dec;27(12):3481-6
pubmed: 22940767
Reprod Biomed Online. 2003 Jun;6(4):439-43
pubmed: 12831590
Gynecol Endocrinol. 2017 Dec;33(12):977-979
pubmed: 28562099
Fertil Steril. 2013 Jan;99(1):5-11
pubmed: 23122826
Gynecol Endocrinol. 2010 Jul;26(7):509-15
pubmed: 20196635
Mol Cell Endocrinol. 2002 May 31;191(1):113-9
pubmed: 12044925
Fertil Steril. 2011 Feb;95(2):679-83
pubmed: 20801436
Hum Reprod. 2009 Feb;24(2):349-59
pubmed: 19054777
Cochrane Database Syst Rev. 2015 Nov 26;(11):CD009749
pubmed: 26608695
Reprod Biomed Online. 2010 Apr;20(4):553-8
pubmed: 20122869
J Assist Reprod Genet. 2012 Mar;29(3):225-30
pubmed: 22160464
Reproduction. 2015 Apr;149(4):R193-218
pubmed: 25516989
Hum Reprod. 2011 Oct;26(10):2742-9
pubmed: 21778283
Endocrinology. 1978 Mar;102(3):876-83
pubmed: 217605
Hum Reprod. 2015 Feb;30(2):315-22
pubmed: 25432927
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004379
pubmed: 20091563
J Pediatr Endocrinol Metab. 1998;11 Suppl 3:891-900
pubmed: 10091163
J Clin Endocrinol Metab. 1998 Nov;83(11):3920-4
pubmed: 9814469
Hum Reprod Update. 2012 Mar-Apr;18(2):127-45
pubmed: 22307331
Biol Reprod. 1999 Aug;61(2):353-7
pubmed: 10411511
Hum Reprod. 1997 Jan;12(1):107-11
pubmed: 9043913

Auteurs

Francesc Fàbregues (F)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Roser Solernou (R)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Janisse Ferreri (J)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Marta Guimerá (M)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Sara Peralta (S)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Gemma Casals (G)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Joana Peñarrubia (J)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Montserrat Creus (M)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Dolors Manau (D)

Institut Clinic de Ginecologia, Obstetricia y Neonatología (ICGON). Hospital Clinic de Barcelona. Institut de Investigacions Biomédiques August Pi iSunyer (IDIBAPS).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH